Epizyme Stock News

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Epizyme, Inc. (Nasdaq: EPZM), a fully integrated, commercial-stage biopharmaceutical company developing and delivering transformative therapies against novel epigene

Metropolitan Life Insurance Co NY raised its stake in Epizyme, Inc. (NASDAQ:EPZM) by 84,150.0% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 20,220 shares of the biopharmaceutical companys stock after acquiring an additional 20,196 shares during the period. Metropolitan Life Insurance []

Epizyme Inc. (NASDAQ:EPZM) traded at $3.20 at close of the session on Monday, 11/29/21, made a downward move of -5.04% on its previous days price. Looking at the stock we see that its previous close was $3.37 and the beta (5Y monthly) reads 1.18 with the days price range being $3.19 $3.47. In terms Think You Need A Good Stock? Look At This Epizyme Inc. (NASDAQ: EPZM) Analysis Read More »

UBS Asset Management Americas Inc. raised its position in Epizyme, Inc. (NASDAQ:EPZM) by 26.4% during the 2nd quarter, Holdings Channel reports. The firm owned 101,289 shares of the biopharmaceutical companys stock after acquiring an additional 21,170 shares during the quarter. UBS Asset Management Americas Inc.s holdings in Epizyme were worth $842,000 at the end of []

Epizyme has been on my watch list for over a year now due to the company's flagship product, TAZVERIK. Unfortunately, the company launched TAZVERIK right into strong COVID-19 headwinds. The company's

Price T Rowe Associates Inc. MD decreased its position in shares of Epizyme, Inc. (NASDAQ:EPZM) by 72.9% during the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 254,366 shares of the biopharmaceutical companys stock after selling 685,865 shares during the quarter. Price T Rowe []

Wall Street brokerages expect Epizyme, Inc. (NASDAQ:EPZM) to post sales of $11.41 million for the current fiscal quarter, Zacks reports. Three analysts have made estimates for Epizymes earnings. The lowest sales estimate is $5.80 million and the highest is $17.42 million. Epizyme reported sales of $8.38 million during the same quarter last year, which indicates []

Northern Trust Corp boosted its stake in shares of Epizyme, Inc. (NASDAQ:EPZM) by 1.7% during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 970,351 shares of the biopharmaceutical companys stock after purchasing an additional 15,887 shares during the period. Northern Trust Corps holdings in Epizyme []

Wall Street analysts expect Epizyme, Inc. (NASDAQ:EPZM) to announce earnings per share (EPS) of ($0.50) for the current fiscal quarter, Zacks Investment Research reports. Three analysts have issued estimates for Epizymes earnings. The lowest EPS estimate is ($0.63) and the highest is ($0.36). Epizyme posted earnings of ($0.65) per share during the same quarter last []

Epizyme (EPZM) posts a wider-than-expected loss in the third quarter and revenues miss estimates. Nevertheless, the pipeline progress is encouraging.

After an infusion of cash from COVID-19 treatments, many companies are on the lookout for acquisitions.

Epizyme, Inc. (EPZM) CEO Grant Bogle on Q3 2021 Results - Earnings Call Transcript

Epizyme (EPZM) delivered earnings and revenue surprises of -42.22% and -40.23%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for the stock?

Epizyme (EPZM) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.